Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2026)
Cogent Biosciences' (COGT) quarterly Income from Continuing Operations came in at 111204000.0 in Q1 2026, down 54.48% year-on-year from 244308732.83 in Q1 2025, and down 1.01% on a QoQ basis from 110097000.0 in Q4 2025.
Cogent Biosciences (COGT) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has 10 years of Income from Continuing Operations data on file, last reported at 111204000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 54.48% year-over-year to 111204000.0 in Q1 2026; TTM through Mar 2026 was 382504000.0, a 43.08% decrease from a year earlier, with the FY2025 full-year figure at 1080622000.0, down 126.83% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 111204000.0, down from 110097000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for COGT reached as high as 35907000.0 in Q1 2022 and fell as low as 111204000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 65904294.12 across 5 years, with a median of 62752000.0 in 2024.
- Across the five-year window, Income from Continuing Operations tumbled 243.33% in 2022 and jumped 36.61% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 39984000.0 in 2022, then slumped by 47.54% to 58994000.0 in 2023, then grew by 4.57% to 56296000.0 in 2024, then tumbled by 95.57% to 110097000.0 in 2025, then fell by 1.01% to 111204000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 111204000.0 in Q1 2026, 110097000.0 in Q4 2025, and 85218000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Cogent Biosciences | 6.45 Bn | 6.45 Bn | - | -111.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -111.20 Mn |
| Dec 31, 2025 | -110.10 Mn |
| Sep 30, 2025 | -85.22 Mn |
| Jun 30, 2025 | -75.99 Mn |
| Mar 31, 2025 | -71.99 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -74.33 Mn |
| Jun 30, 2024 | -64.73 Mn |
| Mar 31, 2024 | -62.75 Mn |
| Dec 31, 2023 | -58.99 Mn |
| Sep 30, 2023 | -59.83 Mn |
| Jun 30, 2023 | -47.30 Mn |
| Mar 31, 2023 | -43.12 Mn |
| Dec 31, 2022 | -39.98 Mn |
| Sep 30, 2022 | -48.03 Mn |
| Jun 30, 2022 | -74.62 Mn |
| Mar 31, 2022 | -35.91 Mn |
| Dec 31, 2021 | -26.82 Mn |
| Sep 30, 2021 | -20.17 Mn |
| Jun 30, 2021 | -21.73 Mn |